Target the underlying cause of
X-linked hypophosphatemia (XLH)
with CRYSVITA® (burosumab-twza)

Learn about CRYSVITA
See clinical data
Review access to CRYSVITA
Attend a CRYSVITA event
CRYSVITA is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months of age and older.1
CRYSVITA has been studied in clinical trials that included 126 children and 148 adults with XLH.
UltraCare® Patient Services provides information on how patients with XLH can access treatment with CRYSVITA.
Learn about the safety and efficacy of CRYSVITA for XLH from an XLH specialist.
IIlustration of mother and daughter living with X-linked hypophosphatemia

How crysvita may help

In clinical trials, CRYSVITA helped normalize serum phosphorus, heal rickets, and increase growth when compared with conventional therapy in pediatric patients with XLH. CRYSVITA also helped normalize serum phosphorus and heal osteomalacia-related fractures and osteomalacia in adults with XLH.

See the clinical data

Help your patients gain access to CRYSVITA

Ultragenyx is committed to patients with rare diseases, which is why we created UltraCare® Patient Services for CRYSVITA, a program that provides information about how your patients can have access to CRYSVITA to treat XLH. Our services are designed to help patients and caregivers understand their insurance coverage and determine their eligibility for financial and patient assistance programs.

Visit UltraCare

Reference
  1. CRYSVITA (burosumab-twza) US Prescribing Information; June 2020.

For specific content related to CRYSVITA for Children or CRYSVITA for Adults, please use these selection tabs as you navigate through the site.

×